Evidence map›Paper›PMID 40317415›Full record

ArticleMolecular neurobiology2025

TAT-T407 Mitigates Apoptosis and Cognitive Impairments Following Cerebral Ischemia Through Disruption of TRPV1-CDK5 Interaction.

Qian Feng, Ying Li, Xiangru Wen, Hui Li, Chengyu Qi, Nan Wang, Guang Zhu, Yanyan Fu, Changdong Liu, Dan Liu and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Qian FengJiangsu Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Jiangsu Key Laboratory of Brain Disease and Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Xuzhou Key Laboratory of Clinical and Experimental Pathology, Key Laboratory of Genetic Foundation and Clinical Application, Department of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.ORCID http://orcid.org/0000-0002-4752-0770
Ying LiClinical Laboratory, Xuzhou Medical University Affiliated Hospital, Xuzhou, Jiangsu, 221002, China.ORCID http://orcid.org/0009-0002-2891-9863
Xiangru WenJiangsu Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Jiangsu Key Laboratory of Brain Disease and Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Xuzhou Key Laboratory of Clinical and Experimental Pathology, Key Laboratory of Genetic Foundation and Clinical Application, Department of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
Hui LiThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Chengyu QiThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Nan WangJiangsu Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Jiangsu Key Laboratory of Brain Disease and Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Xuzhou Key Laboratory of Clinical and Experimental Pathology, Key Laboratory of Genetic Foundation and Clinical Application, Department of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
Guang ZhuDivision of Life Science, The Hong Kong University of Science and Technology, Kowloon, Hong Kong, 999077, China.
Yanyan FuDepartment of Neurobiology and Cell Biology, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Changdong LiuDivision of Life Science, The Hong Kong University of Science and Technology, Kowloon, Hong Kong, 999077, China.
Dan LiuThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Zhen ZhangThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Fan YangThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Zhongyuan ZhouThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Jinjin SongThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Jia LiangThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Yuling ChenThe Graduate School, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China.
Xiaoyan ZhouJiangsu Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Jiangsu Key Laboratory of Brain Disease and Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Xuzhou Key Laboratory of Clinical and Experimental Pathology, Key Laboratory of Genetic Foundation and Clinical Application, Department of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China. zhouxiaoyan0201@xzhmu.edu.cn.
Yan LiuJiangsu Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Jiangsu Key Laboratory of Brain Disease and Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Xuzhou Key Laboratory of Clinical and Experimental Pathology, Key Laboratory of Genetic Foundation and Clinical Application, Department of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China. liuyan@xzhmu.edu.cn.
Yuanjian SongJiangsu Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Jiangsu Key Laboratory of Brain Disease and Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Engineering Center for Precision Diagnosis and Treatment Research of Polygenic Diseases, Xuzhou Key Laboratory of Clinical and Experimental Pathology, Key Laboratory of Genetic Foundation and Clinical Application, Department of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China. yjsong@xzhmu.edu.cn.ORCID http://orcid.org/0000-0002-1845-3732

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral ischemia/reperfusion (I/R) injury manifests as progressive motor and cognitive dysfunction, primarily attributed to neuronal apoptosis. However, there is a lack of neuroprotective drugs targeting neuronal apoptosis in ischemic stroke. In this study, utilizing bioinformatics analysis, we hypothesized that TRPV1 could serve as a novel molecular target implicated in neuronal apoptosis during cerebral ischemia/reperfusion (I/R) injury. To validate our hypothesis in vivo, we employed mouse models of I/R injury induced by transient middle cerebral artery occlusion (tMCAO). Importantly, pre-injecting capsazepine (CPZ), a TRPV1 antagonist, significantly suppressed apoptotic pathway activity in neurons. Additionally, we investigated the regulatory role of CDK5, a well-known neuronal-specific kinase, in modulating the internalization and functionality of TRPV1 ion channels. Our findings revealed an augmented interaction between TRPV1 and CDK5 during cerebral ischemia/reperfusion (I/R) injury. The administration of the TAT-T407 interference peptide, derived from the phosphorylation site of TRPV1 for CDK5, resulted in a reduction of neuronal apoptosis within ischemic regions following cerebral ischemia/reperfusion (I/R) injury. This intervention significantly diminished cerebral infarct volume and improved neurological function. In summary, disrupting the TRPV1/CDK5 interaction through TAT-T407 peptides provides protection against neuronal apoptosis and cognitive decline, suggesting an innovative therapeutic strategy for ischemic stroke treatment.

Indexed as

ApoptosisBrain IschemiaCognitive DysfunctionCyclin-Dependent Kinase 5TRPV Cation ChannelsAnimalsMaleMiceMice, Inbred C57BLNeuronsProtein BindingReperfusion InjuryCdk5 protein, mouseCyclin-Dependent Kinase 5TRPV1 protein, mouseTRPV Cation ChannelsApoptosisCDK5Cerebrovascular disordersPeptideStrokeTRPV1

Identifiers

PMID40317415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.